Longeveron (LGVN) FCF Margin (2020 - 2026)
Longeveron's (LGVN) quarterly FCF Margin came in at 1097.99% in Q1 2026, up 14191.0% year-on-year from N/an in Q1 2025, and up 24.33% quarter-over-quarter from 1450.96% in Q4 2025.
Longeveron (LGVN) FCF Margin (2020 - 2026) Analysis & Trends
Longeveron's FCF Margin history runs 7 years deep, the most recent figure standing at 1097.99% for Q1 2026.
- On a quarterly basis, FCF Margin rose 14191.0% year-over-year to 1097.99% in Q1 2026; TTM through Mar 2026 was 1524.34%, a 79872.0% decrease from a year earlier, with the FY2025 full-year figure at 1575.48%, down 96833.0% from the prior year.
- FCF Margin advanced to 1097.99% in Q1 2026 per LGVN's latest filing, from 1450.96% in the prior quarter.
- Across five years, FCF Margin topped out at 423.42% in Q3 2024 and bottomed at 6604.76% in Q4 2023.
- The 5-year median for FCF Margin is 1354.52% (2022), against an average of 1990.82%.
- Across the five-year window, FCF Margin slumped 464278 bps in 2023 and jumped 604324 bps in 2024, its largest moves.
- Year by year, FCF Margin stood at 1961.98% in 2022, then slumped by 237 bps to 6604.76% in 2023, then surged by 91 bps to 561.53% in 2024, then slumped by 158 bps to 1450.96% in 2025, then gained by 24 bps to 1097.99% in 2026.
- Per Business Quant, the three latest LGVN FCF Margin figures stand at 1097.99% (Q1 2026), 1450.96% (Q4 2025), and 3731.39% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -1,097.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,097.99% |
| Dec 31, 2025 | -1,450.96% |
| Sep 30, 2025 | -3,731.39% |
| Jun 30, 2025 | -1,189.24% |
| Mar 31, 2025 | -1,239.90% |
| Dec 31, 2024 | -561.53% |
| Sep 30, 2024 | -423.42% |
| Jun 30, 2024 | -1,017.52% |
| Mar 31, 2024 | -566.06% |
| Dec 31, 2023 | -6,604.76% |
| Sep 30, 2023 | -3,039.33% |
| Jun 30, 2023 | -2,162.67% |
| Mar 31, 2023 | -2,111.11% |
| Dec 31, 2022 | -1,961.98% |
| Sep 30, 2022 | -4,612.00% |
| Jun 30, 2022 | -719.53% |
| Mar 31, 2022 | -1,354.52% |
| Dec 31, 2021 | -762.20% |
| Sep 30, 2021 | -1,021.98% |
| Jun 30, 2021 | -603.68% |